TY - JOUR
T1 - Comorbid amyloid-β pathology affects clinical and imaging features in VCD
AU - Leijenaar, Jolien F.
AU - Groot, Colin
AU - Sudre, Carole H.
AU - Bergeron, David
AU - Leeuwis, Anna E.
AU - Cardoso, M. Jorge
AU - Carrasco, Ferran Prados
AU - Laforce, Robert
AU - Barkhof, Frederik
AU - van der Flier, Wiesje M.
AU - Scheltens, Philip
AU - Prins, Niels D.
AU - Ossenkoppele, Rik
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Introduction: To date, the clinical relevance of comorbid amyloid-β (Aβ) pathology in patients with vascular cognitive disorders (VCD) is largely unknown. Methods: We included 218 VCD patients with available cerebrospinal fluid Aβ42 levels. Patients were divided into Aβ+ mild-VCD (n = 84), Aβ− mild-VCD (n = 68), Aβ+ major-VCD (n = 31), and Aβ− major-VCD (n = 35). We measured depression with the Geriatric Depression Scale, cognition with a neuropsychological test battery and derived white matter hyperintensities (WMH) and gray matter atrophy from MRI. Results: Aβ− patients showed more depressive symptoms than Aβ+. In the major-VCD group, Aβ− patients performed worse on attention (P = .02) and executive functioning (P = .008) than Aβ+. We found no cognitive differences in patients with mild VCD. In the mild-VCD group, Aβ− patients had more WMH than Aβ+ patients, whereas conversely, in the major-VCD group, Aβ+ patients had more WMH. Atrophy patterns did not differ between Aβ+ and Aβ− VCD group. Discussion: Comorbid Aβ pathology affects the manifestation of VCD, but effects differ by severity of VCD.
AB - Introduction: To date, the clinical relevance of comorbid amyloid-β (Aβ) pathology in patients with vascular cognitive disorders (VCD) is largely unknown. Methods: We included 218 VCD patients with available cerebrospinal fluid Aβ42 levels. Patients were divided into Aβ+ mild-VCD (n = 84), Aβ− mild-VCD (n = 68), Aβ+ major-VCD (n = 31), and Aβ− major-VCD (n = 35). We measured depression with the Geriatric Depression Scale, cognition with a neuropsychological test battery and derived white matter hyperintensities (WMH) and gray matter atrophy from MRI. Results: Aβ− patients showed more depressive symptoms than Aβ+. In the major-VCD group, Aβ− patients performed worse on attention (P = .02) and executive functioning (P = .008) than Aβ+. We found no cognitive differences in patients with mild VCD. In the mild-VCD group, Aβ− patients had more WMH than Aβ+ patients, whereas conversely, in the major-VCD group, Aβ+ patients had more WMH. Atrophy patterns did not differ between Aβ+ and Aβ− VCD group. Discussion: Comorbid Aβ pathology affects the manifestation of VCD, but effects differ by severity of VCD.
KW - Amyloid-β
KW - Cognition
KW - Gray matter atrophy
KW - MRI
KW - Vascular cognitive disorders
KW - Vascular dementia
KW - White matter hyperintensities
UR - http://www.scopus.com/inward/record.url?scp=85075884847&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2019.08.190
DO - 10.1016/j.jalz.2019.08.190
M3 - Article
C2 - 31786129
AN - SCOPUS:85075884847
SN - 1552-5260
VL - 16
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 2
ER -